Plenary Session Presentations
Animal Models for Assessing Countermeasures to Bioterrorism Agents
Linda Anestidou, D.V.M., Ph.D.
EU: Regulatory Procedures for the Authorisation of Vaccines Against Influenza A (H1N1)
Sabine Atzor
Strategic National Stockpile: Overview
Coordinating Office for Terrorism Preparedness and Emergency Response, CDC
Liability Protection for Public Health Countermeasures
John M. Clerici
Canadian MedCM Consortium
R.K. Harding
Emergency Use of Medical Countermeasures
Cynthia L. Kelley, M.S.
Medical Countermeasures Programs on BioDefense, Radiological/Nuclear and Chemical Threats at the National Institute of Allergy and Infectious Diseases
Michael G. Kurilla, M.D., Ph.D.
The Global Health Security Initiative (GHSI) Public Health Emergency Medical Countermeasures (MCM) Workshop
Nigel Lightfoot, C.B.E.
The U.S. Public Health Medical Countermeasure Enterprise
Carol D. Linden, Ph.D.
WHO Coordination Efforts to Make Pandemic (H1N1) Vaccines Available Globally
C. E. Roth
The WHO Smallpox Vaccine Resource
C. E. Roth
The French Medical Countermeasures Program
Road Map and Perspectives
François Salicis
MCM Markets and Sustainability: The National Biodefense Science Board Approach
Patrick J. Scannon, M.D., Ph.D.
Prospects for International Harmonization of the Regulatory Processes for MCM
Dr. David J. Wood
Pandemic Influenza Breakout Session Presentations
Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing
Nathalie Charland, Ph.D.
Multivalent Vaccine Platform for Pandemic influenza and Biodefense
Dr. John Y. Dong
Epidemiology of Infectious Complications of H1N1 Influenza Virus Infection
Lyn Finelli, Dr.PH, M.S.
DMID H1N1 Clinical Trials
Richard L. Gorman, M.D.
HHS/NIH/NIAID Press Releases about H1N1
Richard L. Gorman, M.D.
New Influenza A/H1N1
René Gottschalk, M.D., Ph.D
H1N1 Vaccine & Antivirals
Robin Robinson, Ph.D.
PREPARED—Preparation & Response to the Emerging Pandemic: Assays, Reagents & Enhanced Distribution
Mary Hoelscher
National Pandemic Flu Service: Rapid Antiviral Distribution During H1N1 Pandemic
Bruce Taylor
The Japanese H1N1 Vaccination Strategy
Teppei Kiuchi, M.D., M.P.H.
Biological Threats Breakout Session Presentations
NIAID MCM Research and Development at the Health Protection Agency
Dr. Simon Funnell
Therapeutic Research within the French RNBC Program
Daniel Gillet
Global Health Security Initiative
Cangene Corporation
French Anthrax Vaccine Program
Colonel Françoise Leveque
U.K. Biodefence Medical Countermeasures Portfolio
Nigel Lightfoot, C.B.E.
The Integrated National Biodefense Medical Countermeasures (MCM) Portfolio Initiative
Carol D. Linden, Ph.D.
Advanced Development of a Broad Spectrum Antiviral Drug for the Treatment of Smallpox
George R. Painter, Ph.D.
Emergent’s Anthrax Programs
Emergent Biosolutions
Botulism Diagnostics: Challenges and Requirements
Susan Maslanka, Ph.D.
Developing a New Generation of Anthrax Vaccines and Therapeutics
Dr. Matthew Duchars
Research and Developments in Smallpox Vaccine LC16m8
Tomoya Saito, M.D., Ph.D
Radiological/Nuclear Threats Breakout Session Presentations
Mitigation of the Hematopoietic Syndrome Resulting From Acute Exposure to Ionizing Radiation: A Therapeutic Solution
Timothy Gallaher, Ph.D.
Countermeasures Against Intakes of Radionuclides: Decorporation Research at LRRI
Raymond A. Guilmette, Ph.D., FHPS, CRadP
NIH/NIAID Radionuclide Decorporation Agent Development Program
Nate Hafer, Ph.D.
BARDA Development and Funding: Chemical, Radiological and Nuclear Portfolio
HHS/ASPR/BARDA
Acute and Delayed Effects of ARS: An Animal Model Research Platform to Assess Efficacy of Medical Countermeasures
Thomas J. MacVittie, Ph.D.
Radiological Emergency Preparedness in the United Kingdom—Progress in 2009
Neil McColl
NIAID/NIH Radiation/Nuclear Medical Countermeasures Development Program
Narayani Ramakrishnan, Ph.D.
An Update on WHO Activities on MCM Against Radiation Emergencies
Zhanat Carr, M.D., Ph.D.
Chemical Threats Breakout Session Presentations
Neurotoxins Countermeasures: the French Military Health Service
Lieutenant Colonel Bardot Sébastien, Pharma.D.
HI-6: Oxime Research in Canada, Development of an Intravenous Formulation of HI-6
Defence Research and Development, Canada
CounterACT Summary
Countermeasures Against Chemical Threats
The Oxime Cost-Effective Stockpile: Lessons Learned from Iran and Japan
Tetsu Okumura, M.D., Ph.D.
Overview of MCM Research in Japan
Tetsu Okumura, M.D., Ph.D.
Oxime Research in the U.S.A. and Improving Efficacy in the CNS
Richard K. Gordon, Ph.D.
Executive Summary - in Clearance; will be posted shortly.